NBT Bank N A NY Has $8.51 Million Stock Holdings in Danaher Corporation $DHR

NBT Bank N A NY decreased its holdings in shares of Danaher Corporation (NYSE:DHR) by 1.9% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 43,098 shares of the conglomerate’s stock after selling 837 shares during the period. NBT Bank N A NY’s holdings in Danaher were worth $8,514,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of DHR. GHP Investment Advisors Inc. raised its holdings in Danaher by 396.0% during the first quarter. GHP Investment Advisors Inc. now owns 124 shares of the conglomerate’s stock worth $25,000 after buying an additional 99 shares during the last quarter. Sierra Ocean LLC raised its holdings in shares of Danaher by 116.9% in the first quarter. Sierra Ocean LLC now owns 141 shares of the conglomerate’s stock valued at $29,000 after purchasing an additional 76 shares during the last quarter. Red Tortoise LLC raised its holdings in shares of Danaher by 175.0% in the second quarter. Red Tortoise LLC now owns 154 shares of the conglomerate’s stock valued at $30,000 after purchasing an additional 98 shares during the last quarter. Smallwood Wealth Investment Management LLC purchased a new stake in shares of Danaher in the first quarter valued at about $31,000. Finally, Dunhill Financial LLC raised its holdings in shares of Danaher by 68.4% in the first quarter. Dunhill Financial LLC now owns 165 shares of the conglomerate’s stock valued at $34,000 after purchasing an additional 67 shares during the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher Stock Performance

NYSE DHR opened at $208.63 on Wednesday. Danaher Corporation has a 52-week low of $171.00 and a 52-week high of $279.41. The company has a 50-day simple moving average of $200.40 and a 200 day simple moving average of $197.32. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.22 and a current ratio of 1.62. The company has a market capitalization of $149.39 billion, a PE ratio of 44.39, a price-to-earnings-growth ratio of 3.02 and a beta of 0.77.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.64 by $0.16. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The business had revenue of $5.94 billion during the quarter, compared to the consensus estimate of $5.83 billion. During the same quarter last year, the company posted $1.72 earnings per share. The firm’s quarterly revenue was up 3.4% compared to the same quarter last year. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. On average, research analysts predict that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Friday, September 26th will be given a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date is Friday, September 26th. Danaher’s dividend payout ratio (DPR) is currently 27.23%.

Analyst Upgrades and Downgrades

Several analysts have recently commented on DHR shares. Barclays reiterated an “overweight” rating and issued a $225.00 target price (up previously from $215.00) on shares of Danaher in a report on Tuesday, June 24th. UBS Group lowered their target price on shares of Danaher from $240.00 to $225.00 and set a “buy” rating for the company in a report on Wednesday, July 23rd. Scotiabank upgraded shares of Danaher from a “sector perform” rating to a “sector outperform” rating and set a $275.00 target price for the company in a report on Friday, July 11th. Guggenheim reiterated a “buy” rating and issued a $250.00 target price on shares of Danaher in a report on Wednesday, July 23rd. Finally, Wall Street Zen upgraded shares of Danaher from a “hold” rating to a “buy” rating in a report on Friday, June 27th. Seventeen research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $246.74.

Insiders Place Their Bets

In other Danaher news, Director Teri List sold 2,778 shares of the stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $211.06, for a total transaction of $586,324.68. Following the completion of the transaction, the director owned 20,751 shares in the company, valued at $4,379,706.06. This trade represents a 11.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 11.20% of the stock is owned by corporate insiders.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.